查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1407328

骨生物學市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按產品、按應用、最終用戶、地區和競爭細分

Osteobiologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Application, By End User, By Region, and By Competition
出版日期: | 出版商: TechSci Research | 英文 176 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

預計全球骨生物學市場在預測期內將出現令人印象深刻的成長。全球骨生物製品市場是指醫療產業內快速成長的部門，專門從事旨在增強骨癒合和再生的生物產品和材料的開發和分銷。這些產品通常用於骨科和脊椎外科手術，以促進骨骼生長、修復和融合。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球骨生物學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（同種異體移植物、骨髓抽吸濃縮物、骨形態發生蛋白、去礦物質骨基質、富含血漿的蛋白質、合成骨科生物製劑、黏性補充劑產品）
    • 按應用（骨折恢復、顎面和牙科應用、骨關節炎和退化性關節炎、軟組織損傷、脊椎融合）
    • 按最終使用者（牙科診所和設施、醫院、研究和學術機構、專科診所、其他）
    • 按地區
    • 按公司分類 (2022)
  • 產品市場地圖
    • 按產品分類
    • 按應用
    • 按最終用戶
    • 按地區

第 6 章：北美骨生物學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（同種異體移植物、骨髓抽吸濃縮物、骨形態發生蛋白、去礦物質骨基質、富含血漿的蛋白質、合成骨科生物製劑、黏性補充劑產品）
    • 按應用（骨折恢復、顎面和牙科應用、骨關節炎和退化性關節炎、軟組織損傷、脊椎融合）
    • 按最終使用者（牙科診所和設施、醫院、研究和學術機構、專科診所、其他）
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲骨生物學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（同種異體移植物、骨髓抽吸濃縮物、骨形態發生蛋白、去礦物質骨基質、富含血漿的蛋白質、合成骨科生物製劑、黏性補充劑產品）
    • 按應用（骨折恢復、顎面和牙科應用、骨關節炎和退化性關節炎、軟組織損傷、脊椎融合）
    • 按最終使用者（牙科診所和設施、醫院、研究和學術機構、專科診所、其他）
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙

第 8 章：亞太地區骨生物學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（同種異體移植物、骨髓抽吸濃縮物、骨形態發生蛋白、去礦物質骨基質、富含血漿的蛋白質、合成骨科生物製劑、黏性補充劑產品）
    • 按應用（骨折恢復、顎面和牙科應用、骨關節炎和退化性關節炎、軟組織損傷、脊椎融合）
    • 按最終使用者（牙科診所和設施、醫院、研究和學術機構、專科診所、其他）
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國

第 9 章：南美洲骨生物學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（同種異體移植物、骨髓抽吸濃縮物、骨形態發生蛋白、去礦物質骨基質、富含血漿的蛋白質、合成骨科生物製劑、黏性補充劑產品）
    • 按應用（骨折恢復、顎面和牙科應用、骨關節炎和退化性關節炎、軟組織損傷、脊椎融合）
    • 按最終使用者（牙科診所和設施、醫院、研究和學術機構、專科診所、其他）
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲骨生物學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（同種異體移植物、骨髓抽吸濃縮物、骨形態發生蛋白、去礦物質骨基質、富含血漿的蛋白質、合成骨科生物製劑、黏性補充劑產品）
    • 按應用（骨折恢復、顎面和牙科應用、骨關節炎和退化性關節炎、軟組織損傷、脊椎融合）
    • 按最終使用者（牙科診所和設施、醫院、研究和學術機構、專科診所、其他）
    • 按國家/地區
  • MEA：國家分析
    • 南非骨生物學
    • 沙烏地阿拉伯骨生物學
    • 阿拉伯聯合大公國骨生物學
    • 科威特骨生物學

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • 商業概覽
  • 產品供應
  • 最近的發展
  • 財務（據報導）
  • 主要人員
  • SWOT分析
    • Stryker Corp
    • DePuy Synthes Inc
    • Medtronic PLC
    • Osteomed LP
    • Zimmer Biomet Holdings, Inc.
    • Smith & Nephew plc
    • Genzyme Corp
    • Arthrex Inc
    • Orthofix International BV

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄
Product Code: 20592

Global Osteobiologics Market is anticipated to project impressive growth in the forecast period. The global osteobiologics market refers to a rapidly growing sector within the medical industry that specializes in the development and distribution of biological products and materials designed to enhance bone healing and regeneration. These products are commonly used in orthopedic and spinal surgical procedures to facilitate bone growth, repair, and fusion.

Key Market Drivers

Aging Population

The global healthcare landscape is experiencing a seismic shift, with one of the most significant factors being the rapidly aging population. As life expectancy increases and birth rates decline, the world is witnessing a demographic transformation. This aging demographic is not just impacting the social and economic fabric but also plays a pivotal role in shaping the healthcare industry.

With aging, the risk of orthopedic disorders such as osteoarthritis, osteoporosis, and degenerative joint diseases significantly increases. These conditions often result in fractures, joint degeneration, and the need for orthopedic surgeries. Osteobiologics, biological products that aid bone healing and regeneration, have become a vital component in the treatment of these disorders, providing an ideal environment for bone fusion and faster recovery.

Falls and fractures become more common as individuals age, mainly due to decreased bone density and muscle mass. Osteobiologics, including bone grafts and growth factors, are instrumental in accelerating the healing of fractures, reducing complications, and improving the overall quality of life for the elderly.

The aging population often requires orthopedic and spinal surgeries to address issues like herniated discs, spinal stenosis, and joint replacements. Osteobiologics play a vital role in these surgical procedures by promoting bone fusion and regeneration, thereby enhancing surgical outcomes and reducing the need for revision surgeries.

Maintaining mobility and independence is a top priority for the elderly. Osteobiologics facilitates a faster and more effective healing process, enabling older individuals to regain mobility sooner. This, in turn, boosts their overall quality of life and reduces the burden on healthcare systems by minimizing the need for prolonged care and rehabilitation.

Advancements in biotechnology have led to the development of more sophisticated osteobiologic products. These innovations have improved the effectiveness and safety of these products, making them more suitable for the aging population. Growth factor therapies and synthetic graft materials are just a couple of examples of these advancements, providing more options for surgeons and patients.

The aging population is more informed and proactive about their health and treatment options than ever before. With access to information through the internet and increased awareness campaigns, older individuals are more likely to seek out medical procedures that offer faster recovery times and reduced complications, which osteobiologics can provide.

Increasing Orthopedic Procedures

The global osteobiologics market is witnessing substantial growth, and one of the key drivers behind this expansion is the increasing prevalence of orthopedic procedures. Osteobiologics, which encompasses a range of biological materials and products designed to enhance bone healing and regeneration, has become pivotal in addressing the needs of patients with orthopedic conditions.

The world's population is aging at an unprecedented rate. As people grow older, they become more susceptible to orthopedic conditions such as osteoarthritis, degenerative joint diseases, and fractures. This demographic shift has led to a surge in orthopedic procedures, as aging individuals seek treatments to maintain their mobility and quality of life. Osteobiologics have become an indispensable part of these procedures, as they promote bone fusion and faster recovery, reducing complications and the need for revision surgeries.

The modern lifestyle, characterized by increased physical activity and sports participation, has led to a rise in orthopedic injuries, including torn ligaments, damaged cartilage, and stress fractures. Athletes and active individuals often require orthopedic surgeries to address these injuries. Osteobiologics play a crucial role in accelerating bone healing and tissue regeneration, thereby reducing recovery times and enabling a swift return to sports and activities.

Orthopedic procedures like joint replacements have become more common due to the aging population and the prevalence of conditions like osteoarthritis. These procedures involve the replacement of damaged joints with prosthetic implants. Osteobiologics are instrumental in ensuring the success of these surgeries by promoting bone growth around the implants, enhancing implant stability, and extending the life of the prosthetic joint.

Conditions like herniated discs, spinal stenosis, and deformities often necessitate spinal surgeries. As these procedures become more prevalent, osteobiologics play a vital role in facilitating spinal fusion and stabilization. Patients benefit from reduced pain, faster recovery, and improved spinal function, all of which are made possible through the use of these biologically active materials.

Advancements in surgical techniques have led to a shift towards minimally invasive procedures. These techniques offer numerous advantages, including smaller incisions, reduced trauma to surrounding tissues, and quicker recovery times. Osteobiologics are particularly well-suited for minimally invasive procedures, as they enhance bone regeneration while minimizing surgical trauma.

The orthopedic industry continues to witness significant research and innovation aimed at enhancing patient outcomes. Researchers and manufacturers are developing new osteobiologic products, materials, and delivery methods. These innovations are designed to improve the efficacy and safety of osteobiologics, further supporting their use in orthopedic procedures.

Advances in Biotechnology

The global osteobiologics market, which centers on biological products and materials that enhance bone healing and regeneration, is experiencing remarkable growth. One of the most significant catalysts behind this expansion is the continuous evolution of biotechnology. As biotechnological innovations lead to more sophisticated osteobiologic products, the market is witnessing a surge in demand.

Biotechnology has revolutionized the development of osteobiologic products. With the use of cutting-edge techniques, researchers and manufacturers can engineer materials with improved efficacy and safety. Growth factor therapies, synthetic graft materials, and advanced scaffolds are examples of biotechnological advancements that are offering more effective solutions for bone healing and regeneration.

Advances in biotechnology allow for personalized medicine in the field of osteobiologics. Researchers can now tailor treatments to an individual's specific needs, optimizing the therapeutic outcome. This personalized approach ensures that patients receive the most appropriate osteobiologic product for their condition, leading to better outcomes and reduced complications.

Growth factors are essential in promoting bone healing. Biotechnology has enabled the development of bioengineered growth factors that can stimulate bone formation and repair. These factors can be precisely controlled and delivered to the target area, facilitating faster and more efficient bone regeneration.

Biotechnology has ushered in the era of novel biomaterials for use in osteobiologics. These materials can be designed with specific properties to match the mechanical and structural requirements of various clinical scenarios. The creation of synthetic grafts and scaffolds, often inspired by natural bone structure, provides surgeons with versatile and reliable options for bone regeneration.

Biotechnology has enabled the development of advanced delivery systems for osteobiologics. These systems can precisely control the release of growth factors and other therapeutic agents, ensuring they are delivered at the right time and in the right place. This controlled release enhances the effectiveness of osteobiologic treatments.

Biotechnology ensures that osteobiologic products meet stringent safety and purity standards. Products derived through biotechnological processes are subject to rigorous quality control, reducing the risk of complications and adverse reactions in patients. This has contributed to the overall confidence in osteobiologic therapies.

Regenerative Medicine

The global osteobiologics market is witnessing remarkable growth, and one of the key drivers behind this expansion is the burgeoning field of regenerative medicine. Regenerative medicine aims to harness the body's natural healing mechanisms to repair and regenerate damaged or diseased tissues.

Regenerative medicine is rooted in the concept of using the body's own regenerative potential to heal and repair damaged tissues. In the context of osteobiologics, this approach aligns perfectly with the goal of promoting bone healing and regeneration. By enhancing and guiding the body's natural processes, regenerative medicine empowers osteobiologic products to achieve better therapeutic outcomes.

Regenerative medicine introduces innovative treatment modalities that incorporate stem cells, growth factors, and tissue engineering. These modalities can significantly enhance the efficacy of osteobiologic products. For instance, stem cell therapies can be combined with osteobiologics to stimulate more robust bone regeneration, making them a powerful duo in orthopedic and spinal procedures.

One of the key objectives of regenerative medicine is to reduce the need for invasive surgical procedures. By promoting tissue repair and regeneration, regenerative medicine can alleviate the severity of orthopedic and spinal conditions, thus reducing the necessity for extensive surgeries. This benefits both patients and the healthcare system.

The incorporation of regenerative medicine principles into osteobiologics accelerates the healing process. Patients experience faster recovery times and reduce post-operative complications, leading to improved overall outcomes. This not only enhances patient satisfaction but also contributes to the cost-effectiveness of healthcare delivery.

Regenerative medicine allows for a personalized approach to treatment. Through genetic and cellular profiling, physicians can tailor osteobiologic treatments to meet the unique needs of each patient. This level of customization optimizes therapeutic outcomes and reduces the risk of complications.

Key Market Challenges

Cost of Production

The production of osteobiologic products can be expensive due to the need for advanced biotechnological processes and stringent quality control. The cost of materials and manufacturing can be a significant barrier to market entry for smaller companies and can influence product pricing, potentially limiting patient access to these innovative treatments.

Reimbursement Issues

Despite the clinical benefits of osteobiologic products, obtaining favorable reimbursement from insurance providers can be challenging. Many insurance companies may not fully cover the costs of these treatments, leading to out-of-pocket expenses for patients or creating financial hurdles that limit their access to osteobiologic therapies. Companies and healthcare providers must advocate for improved reimbursement policies.

Long Development Timelines

Developing osteobiologic products is a time-consuming process, from the initial research phase to clinical trials and regulatory approvals. The extended development timelines can lead to delays in bringing innovative treatments to the market. These delays may affect patients who are eagerly awaiting better therapeutic options.

Key Market Trends

Advanced Biomaterials and Biologics

The development of innovative biomaterials and biologics is at the forefront of the osteobiologics market. Researchers are creating new materials that mimic natural bone structures more closely and enhance the body's regenerative abilities. This includes 3D-printed implants, engineered growth factors, and synthetic grafts.

Combination Therapies

The practice of combining osteobiologics with other therapies, such as stem cell treatments, is on the rise. This approach can further accelerate bone healing and regeneration. It's becoming increasingly common for surgeons to use a combination of treatments to maximize patient outcomes.

Robotics and Digital Health

The integration of robotics and digital health technologies is changing the landscape of orthopedic surgeries. Robotics-assisted procedures are improving surgical precision and enhancing the placement of osteobiologic products. Digital health tools are being used for remote monitoring and post-operative care.

Segmental Insights

Product Insights

Based on the category of Product, the Plasma-Rich Protein (PRP) is poised to capture a substantial market share in the Global Osteobiologics Market during the forecast period for several compelling reasons. Firstly, PRP offers a minimally invasive and cost-effective alternative for promoting bone healing and tissue regeneration, making it an attractive choice for both patients and healthcare providers. Moreover, its proven efficacy in enhancing the body's natural healing processes and reducing recovery times positions PRP as a preferred option in orthopedic and dental surgeries, which are on the rise globally. Additionally, the increasing awareness of the benefits of PRP in accelerating healing and reducing complications, along with its versatility in various applications, including sports medicine and aesthetics, further cements its dominance in the Osteobiologics market. As a result, PRP is set to become a frontrunner in this market, fostering growth and innovation in the orthobiologics sector.

Application Insights

Based on Application, the Maxillofacial and Dental Applications segment is poised to secure a substantial market share during the forecast period in the Global Osteobiologics Market for a multitude of compelling reasons. First and foremost, the rising prevalence of dental and maxillofacial conditions, coupled with an aging global population, underscores the growing demand for advanced solutions in this sector. Osteobiologics offer a range of innovative and effective treatment options for these specific applications, such as bone grafts and growth factors, significantly enhancing patient outcomes and reducing recovery times. Furthermore, ongoing technological advancements and the increasing adoption of minimally invasive procedures have fueled the attractiveness of osteobiologics in this niche, as they provide safer and more efficient alternatives to traditional treatments. With growing awareness among both healthcare professionals and patients regarding the advantages of osteobiologics in maxillofacial and dental applications, this segment is poised to be a significant driver of growth in the Global Osteobiologics Market, making it a key area of focus for industry stakeholders.

Regional Insights

North America is poised to dominate the Global Osteobiologics Market for several compelling reasons. Firstly, the region benefits from a highly developed healthcare infrastructure and a robust research and development ecosystem, which fosters innovation and rapid adoption of cutting-edge medical technologies. Furthermore, a significant portion of the North American population is aging, driving increased demand for orthopedic and dental procedures, in which osteobiologics play a crucial role. The well-established reimbursement policies and insurance coverage for these procedures in North America also facilitate patient access and affordability, making it an attractive market for osteobiologic products. Moreover, the presence of key market players, extensive clinical trials, and regulatory support further bolster the region's position in this market. With a strong focus on research, accessibility to healthcare, and a willingness to embrace innovative medical solutions, North America is positioned to maintain its dominance in the Global Osteobiologics Market.

Key Market Players

Stryker Corp

DePuy Synthes Inc

Medtronic PLC

Osteomed LP

Zimmer Biomet Holdings, Inc.

Smith & Nephew plc

Genzyme Corp

Arthrex Inc

Orthofix International BV

Report Scope:

In this report, the Global Osteobiologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Osteobiologics Market, By Product:

  • Allografts
  • Bone Marrow Aspirate Concentrate
  • Bone Morphogenic Protein
  • Demineralized Bone Matrices
  • Plasma-Rich Protein
  • Synthetic Orthobiologics
  • Visco-Supplementation Products

Osteobiologics Market, By Application:

  • Fracture Recovery
  • Maxillofacial & Dental Applications
  • Osteoarthritis & Degenerative Arthritis
  • Soft-Tissue Injuries
  • Spinal Fusion

Osteobiologics Market, By End User:

  • Dental Clinics & Facilities
  • Hospitals
  • Research & Academic Institutes
  • Specialty Clinics
  • Others

Osteobiologics Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Osteobiologics Market.

Available Customizations:

  • Global Osteobiologics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Osteobiologics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Allografts, Bone Marrow Aspirate Concentrate, Bone Morphogenic Protein, Demineralized Bone Matrices, Plasma-Rich Protein, Synthetic Orthobiologics, Visco-Supplementation Products)
    • 5.2.2. By Application (Fracture Recovery, Maxillofacial & Dental Applications, Osteoarthritis & Degenerative Arthritis, Soft-Tissue Injuries, Spinal Fusion)
    • 5.2.3. By End User (Dental Clinics & Facilities, Hospitals, Research & Academic Institutes, Specialty Clinics, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Product Market Map
    • 5.3.1. By Product
    • 5.3.2. By Application
    • 5.3.3. By End User
    • 5.3.4. By Region

6. North America Osteobiologics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product (Allografts, Bone Marrow Aspirate Concentrate, Bone Morphogenic Protein, Demineralized Bone Matrices, Plasma-Rich Protein, Synthetic Orthobiologics, Visco-Supplementation Products)
    • 6.2.2. By Application (Fracture Recovery, Maxillofacial & Dental Applications, Osteoarthritis & Degenerative Arthritis, Soft-Tissue Injuries, Spinal Fusion)
    • 6.2.3. By End User (Dental Clinics & Facilities, Hospitals, Research & Academic Institutes, Specialty Clinics, Others)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Osteobiologics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Osteobiologics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Osteobiologics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Osteobiologics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product (Allografts, Bone Marrow Aspirate Concentrate, Bone Morphogenic Protein, Demineralized Bone Matrices, Plasma-Rich Protein, Synthetic Orthobiologics, Visco-Supplementation Products)
    • 7.2.2. By Application (Fracture Recovery, Maxillofacial & Dental Applications, Osteoarthritis & Degenerative Arthritis, Soft-Tissue Injuries, Spinal Fusion)
    • 7.2.3. By End User (Dental Clinics & Facilities, Hospitals, Research & Academic Institutes, Specialty Clinics, Others)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Osteobiologics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Osteobiologics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. France Osteobiologics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Osteobiologics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Osteobiologics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia-Pacific Osteobiologics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product (Allografts, Bone Marrow Aspirate Concentrate, Bone Morphogenic Protein, Demineralized Bone Matrices, Plasma-Rich Protein, Synthetic Orthobiologics, Visco-Supplementation Products)
    • 8.2.2. By Application (Fracture Recovery, Maxillofacial & Dental Applications, Osteoarthritis & Degenerative Arthritis, Soft-Tissue Injuries, Spinal Fusion)
    • 8.2.3. By End User (Dental Clinics & Facilities, Hospitals, Research & Academic Institutes, Specialty Clinics, Others)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Osteobiologics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. Japan Osteobiologics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. India Osteobiologics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. Australia Osteobiologics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. South Korea Osteobiologics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. South America Osteobiologics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product (Allografts, Bone Marrow Aspirate Concentrate, Bone Morphogenic Protein, Demineralized Bone Matrices, Plasma-Rich Protein, Synthetic Orthobiologics, Visco-Supplementation Products)
    • 9.2.2. By Application (Fracture Recovery, Maxillofacial & Dental Applications, Osteoarthritis & Degenerative Arthritis, Soft-Tissue Injuries, Spinal Fusion)
    • 9.2.3. By End User (Dental Clinics & Facilities, Hospitals, Research & Academic Institutes, Specialty Clinics, Others)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Osteobiologics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Osteobiologics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Osteobiologics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. Middle East and Africa Osteobiologics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product (Allografts, Bone Marrow Aspirate Concentrate, Bone Morphogenic Protein, Demineralized Bone Matrices, Plasma-Rich Protein, Synthetic Orthobiologics, Visco-Supplementation Products)
    • 10.2.2. By Application (Fracture Recovery, Maxillofacial & Dental Applications, Osteoarthritis & Degenerative Arthritis, Soft-Tissue Injuries, Spinal Fusion)
    • 10.2.3. By End User (Dental Clinics & Facilities, Hospitals, Research & Academic Institutes, Specialty Clinics, Others)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Osteobiologics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Osteobiologics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Osteobiologics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User
    • 10.3.4. Kuwait Osteobiologics Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Product
        • 10.3.4.2.2. By Application
        • 10.3.4.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Stryker Corp
    • 14.6.2. DePuy Synthes Inc
    • 14.6.3. Medtronic PLC
    • 14.6.4. Osteomed LP
    • 14.6.5. Zimmer Biomet Holdings, Inc.
    • 14.6.6. Smith & Nephew plc
    • 14.6.7. Genzyme Corp
    • 14.6.8. Arthrex Inc
    • 14.6.9. Orthofix International BV

15. Strategic Recommendations

16. About Us & Disclaimer